Grey Wolf Therapeutics, the biotechnology company focused on generating novel anti-tumour immune responses through targeted cancer neoantigen creation, has closed a $40 million Series B funding round co-led by Pfizer Ventures.

Grey Wolf said the funding will support the continued development of its “first-of-a-kind” immuno-oncology approaches that are designed to overcome key resistance mechanisms through the creation of novel cancer antigens.

The approach works in part by driving the generation and presentation of novel and potent cancer antigens to the surface of tumour cells.

"This syndicate of leading life science industry investors brings a wealth of relevant expertise and resources to Grey Wolf at a critical time in our evolution as we prepare to enter the clinic," said Peter Joyce, chief executive of Grey Wolf Therapeutics.

Joyce continued: "The funding these groups have committed to Grey Wolf will not only support our efforts to demonstrate clinical proof-of-concept for ERAP inhibition with our lead programme.”

Joyce added that the funding would also help drive its continued scientific exploration and research into immuno-oncology.

Share Story: